Strategy for the treatment of cognitive disorders in patients with chronic brain ischemia and initial manifestations of insufficient blood supply to the brain


chronic cerebral ischemia, initial manifestations of insufficient blood supply of the brain, cognitive disoders, memokor, neokardil, extract ginkgo biloba, piracetam.

How to Cite

Svyrydova, N., & Pavliuk, N. (2015). Strategy for the treatment of cognitive disorders in patients with chronic brain ischemia and initial manifestations of insufficient blood supply to the brain. East European Journal of Neurology, (5(5), 27-32.


Cerebrovascular accidents are the most important med- ical and social problem due to their high frequency in the structure of morbidity and mortality, as well as significant indicators of disability in the population. The severity of cognitive deficits in patients with cerebrovascular disease are more correlated not with territorial infarcts caused by the defeat of the major cerebral arteries, and on microvascular pathology (a minor heart attack, multiple lacunar infarcts, microbleeds), as well as cerebral atrophy, which may be due to vascular brain damage and specific neurodegenerative process. Since effective therapeutic drugs treat persistent cognitive impairment in the present does not exist, an alternative could be a strategy of weakening of cognitive impairment and their progression. The article describes the characteristics, the description of the results of worldwide research application components that are complex and herbal preparations Memokor Neokardil.


[1] Дамулин И.В., Захаров В.В. Дисциркуляторная энцефалопатия: Метод. рекоменд. / Под ред. Н.Н. Яхно. – М., 2000. – 31 с.
[2] Шмырев В.И. Дисциркуляторная энцефалопатия – вопросы патогенеза, диагностики, дифференциальной диагностики и лечения на современном этапе / Шмырев В.И., Васильев А.С., Рудас М.С. // Ліки України. – 2010. – №9 (145). – С. 62–69.
[3] Камчатнов П.Р. Комбинированная терапия дисциркуляторной энцефалопатии / Камчатнов П.Р., Чугунов А.В., Воловец С.А., Умарова Х.Я. // Сonsilium medicum. – 2005. – №7 (8). – С. 686–692.
[4] Мурашко Н.К. Хроническая ишемия мозга / Мурашко Н.К., Кусткова А.С. // Мистецтво лікування. – 2011. - № 10 (86). - С.37-42.
[5] Свиридова Н.К. Новая стратегия лечения когнитивных нарушений / Н.К. Свиридова // Східно-європейський неврологічний журнал. – 2015.- № 3 (3). – С. 39-43
[6] Renshaw PF, Babb SM, Yurgelun-Todd DA et al. Chronic citicholine (CDP-choline administration alters brain phospholipid metabolites and improves cognitive performance in healthy, older adults. 37th ACNP Annual Meeting: Puerto Rico. – 1998.- Р. 1121—1130.
[7] Gao Q.Opening the calcium-activated potassium channel participates in the cardioprotective effect of puerarin / Gao Q, Yang B, Ye ZG et al. // Eur J Pharmacol. – 2007. – Vol. 574. – Р.179-184.
[8] Xu X. The neuroprotection of puerarin against cerebral ischemia is associated with the prevention of apoptosis in rats / Xu X, Zhang S, Zhang L, Yan W, Zheng X // Planta Med. – 2005. – Vol.71. – Р.585-591.
[9] Min-Kyung Choo. Antithrombotic and Antiallergic Activities of Daidzein, a Metabolite of Puerarin and Daidzin Produced by Human Intestinal Microflora. / Min-Kyung Choo, Eun-Kyung Park, Hae-Kyung Yoon, Dong-Hyun Kim // Biological and Pharmaceutical Bulletin. – 2002. – Vol. 25. – N.10. – Р.1328-1332.
[10] Winblad B. Piracetam: a review of pharmacological properties and clinical use // CNS Drug Rev. – 2005. – Vol. 11. – P. 169–182.
[11] Tony Waegemans. Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis / Tony Waegemans, Colin R. Wilsher, Anne Danniau, Steven H. Ferris, Alexander Kurz,
Bengt Winblad // Dementia. – 2002. – Vol. 13. – Р.217-224 [12] Malykh Andrei G., M. Reza Sadaie.Piracetam and piracetamike drugs. From basic science to novel clinical applications to CNS disorders. – Drugs. – 2010. - Vol. 70(3). – Р.287–312.
[13] Воронина Т.А., Середенин С.Б. Ноотропные препараты, достижения и перспективы // Эксп. клин. фармакол. – 1998. – №4. – С. 3–9
[14] Абдулина О.В. Пирацетам: от механизма действия к лечению когнитивных расстройств // РМЖ. – 2010. – Т. 18, №26. – С. 1596–1601.
[15] Долженко М.М., Нудченко О.О., Лур’є С.З., Камінська Х.А., Базилевич А.Я., Філімонова І.В. Оценка эффективности применения препарата Неокардил для уменьшения факторов риска развития сердечно-сосудистой системы при первичной профилактике// Сімейна медицина – 2014 №6(56)